BVS Bioventus Inc.
Healthcare$9.09+0.00%OpenMarket Cap: $615.8M
As of 2026-05-26
Valuation
P/E (TTM)
26.85
PEG
0.16
P/B
3.31
P/S
1.09
EV/EBITDA
5.68
DCF Value
$-2.37
FCF Yield
16.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
67.8%
Operating Margin
10.6%
Net Margin
4.9%
ROE
16.3%
ROA
4.4%
ROIC
11.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $132.1M | 67.9% | $8.9M | $3.1M | $— | — |
| Q4 null | $157.9M | 68.1% | $21.7M | $14.8M | $— | — |
| FY null | $568.1M | 67.3% | $58.5M | $22.7M | $— | — |
| Q3 null | $138.7M | 67.0% | $12.1M | $3.2M | $— | — |
| Q2 null | $147.7M | 68.2% | $18.6M | $7.5M | $— | — |
| Q1 null | $123.9M | 65.8% | $5.0M | $-2.6M | $— | — |
| Q4 null | $153.6M | 66.8% | $8.0M | $-156.0K | $— | — |
| FY null | $573.3M | 67.7% | $-12.0M | $-33.5M | $— | — |
| Q3 null | $139.0M | 67.3% | $4.1M | $-4.8M | $— | — |
| Q2 null | $151.2M | 68.5% | $-31.5M | $-25.7M | $— | — |
| Q1 null | $129.5M | 68.3% | $4.9M | $-4.9M | $— | — |
| Q4 2023 | $135.4M | 63.7% | $1.2M | $-6.1M | $-0.10 | — |